FIGURE 3.

Incidence of severe exacerbations during the 6-months follow-up between different clinical features for symptomatic COPD patients. Note: For comparison, the chi-squared test was used for categorical variables. ns indicates p-values ≥0.05, * indicates p-values <0.05, ** indicates p-values <0.01. Abbreviations: BMI, body mass index; CAT, COPD assessment test; mMRC, modified medical research council dyspnea scale; COPD severity was classified using Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid.